KYORIN Pharmaceutical (4569) · InitiativeReframed
Laying the Foundation for Early Out-Licensing in Europe and the United States and Direct Expansion in Asia
First written in FY2017. 1 of 3 entries say "Restated". Latest entry: FY2020.
3entries
4years
0from disclosures
How it moved
Same theme, other companies
Building an overseas monetization base through licensing in Europe and North America and direct entry into AsiaA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2020ReframedAnnual report
「Business Strategy ⒠ Expanding overseas revenue」
Whereas the previous wording referred to early out-licensing in Europe and the United States and building the foundation for direct expansion in Asia, Stage 3 explicitly identifies overseas revenue growth as a business strategy. - FY2019RestatedAnnual report
「Overseas expansion: deploying innovative new drugs developed in-house, including early out-licensing in Europe and the United States, and laying the groundwork for future direct expansion, primarily in Asia, in prescription pharmaceuticals and healthcare」
The company continues to pursue building the foundation for early out-licensing in Europe and the United States and future direct expansion, primarily in Asia, as its growth strategy. - FY2017First statedAnnual report
「Overseas expansion: deploy innovative new drugs created in-house through early out-licensing in Europe and the United States, while laying the foundation for future direct expansion, primarily in Asia, in prescription pharmaceuticals and healthcare.」
The development strategy calls for early out-licensing of internally created new drugs in Europe and the United States and building a foundation for future direct expansion, primarily in Asia.